Invesco Biotechnology & Genome ETF (PBE) Declares $0.8106 Dividend, Marking Significant Payout Increase
核心洞察
Invesco Biotechnology & Genome ETF (NYSE: PBE) declared a dividend of $0.8106 per share on June 18, 2026, payable June 26, 2026.
The declared dividend represents a substantial increase of $0.7282 from the prior payout, reflecting strong distribution growth.
PBE has maintained dividend payments since 2009 and has now increased its dividends for two consecutive years.
The Invesco Biotechnology & Genome ETF (NYSE: PBE), part of the Invesco Exchange-Traded Fund Trust (搜索), declared a dividend of $0.8106 per share on June 18, 2026. The dividend is payable on June 26, 2026, to shareholders of record as of June 22, 2026. This marks a notable increase of $0.7282 compared to the fund's last dividend paid, signaling robust distribution growth for the biotechnology-focused exchange-traded fund.
PBE has a long-standing track record of returning capital to investors, having paid dividends since 2009. With this latest declaration, the fund has now increased its dividends for two successive years. The current dividend yield stands at approximately 1.84%.
The fund's market capitalization is $443.31 million, with its stock price closing at $84.44 on the most recent trading day. PBE has traded within a 52-week range of $62.63 to $85.73, positioning the current price near the upper end of its annual performance band.
PBE, formally known as the PowerShares Dynamic Biotech & Genome Portfolio, is structured as an open-end management investment company. The fund seeks investment results that correspond generally to the price and yield of the Dynamic Biotechnology & Genome Intellidex Index. This underlying index consists of stocks from 30 United States biotechnology and genome companies—firms principally engaged in the research, development, manufacture, marketing, and distribution of various biotechnological products, services, and processes.
The dividend announcement comes amid broader activity in the biotechnology ETF space. For comparison, the iShares Biotechnology ETF (NASDAQ: IBB), which tracks the NASDAQ Biotechnology Index, declared a dividend of $0.0238 per share on June 12, 2026—a decrease of $0.098 from its prior dividend. IBB, with a substantially larger market capitalization of $11.09 billion, offers a dividend yield of approximately 0.24% and has paid dividends since 2007.
The significant dividend increase by PBE highlights the fund's capacity to generate and distribute income from its portfolio of biotechnology and genome companies, offering investors both exposure to the biotech sector and a growing income stream.